Cargando…
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
BACKGROUND: Despite immune checkpoint inhibitors (ICI) being widely used to treat patients with advanced non-small cell lung cancer (NSCLC), few studies examine the role of ICI in patients with proto-oncogene B-Raf, serine/threonine kinase (BRAF) mutations. METHODS: A retrospective study was conduct...
Autores principales: | Wang, Haowei, Cheng, Lei, Zhao, Chao, Zhou, Fei, Jiang, Tao, Guo, Haoyue, Shi, Jinpeng, Chen, Peixin, Tang, Zhuoran, Mao, Shiqi, Jia, Keyi, Ye, Lingyun, Cai, Chenlei, Li, Xuefei, Chen, Xiaoxia, Zhou, Caicun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989805/ https://www.ncbi.nlm.nih.gov/pubmed/36895926 http://dx.doi.org/10.21037/tlcr-22-613 |
Ejemplares similares
-
Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer
por: Shi, Jinpeng, et al.
Publicado: (2023) -
Computational recognition of LncRNA signatures in tumor-associated neutrophils could have implications for immunotherapy and prognostic outcome of non-small cell lung cancer
por: Tang, Zhuoran, et al.
Publicado: (2022) -
The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021) -
Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019) -
Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy
por: Wang, Haowei, et al.
Publicado: (2022)